Literature DB >> 36240755

Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer.

Annika Fendler1, Scott T C Shepherd2, Lewis Au2, Mary Wu3, Ruth Harvey4, Katalin A Wilkinson5, Andreas M Schmitt6, Zayd Tippu2, Benjamin Shum2, Sheima Farag6, Aljosja Rogiers6, Eleanor Carlyle6, Kim Edmonds6, Lyra Del Rosario6, Karla Lingard6, Mary Mangwende6, Lucy Holt6, Hamid Ahmod6, Justine Korteweg6, Tara Foley6, Taja Barber1, Andrea Emslie-Henry1, Niamh Caulfield-Lynch1, Fiona Byrne1, Daqi Deng1, Svend Kjaer7, Ok-Ryul Song8, Christophe J Queval8, Caitlin Kavanagh3, Emma C Wall9, Edward J Carr10, Simon Caidan11, Mike Gavrielides12, James I MacRae13, Gavin Kelly14, Kema Peat6, Denise Kelly6, Aida Murra6, Kayleigh Kelly6, Molly O'Flaherty6, Robyn L Shea15, Gail Gardner16, Darren Murray16, Sanjay Popat17, Nadia Yousaf18, Shaman Jhanji19, Kate Tatham19, David Cunningham20, Nicholas Van As21, Kate Young6, Andrew J S Furness6, Lisa Pickering6, Rupert Beale22, Charles Swanton23, Sonia Gandhi24, Steve Gamblin25, David L V Bauer26, George Kassiotis27, Michael Howell8, Emma Nicholson28, Susanna Walker19, Robert J Wilkinson29, James Larkin30, Samra Turajlic31.   

Abstract

Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the CAPTURE study (NCT03226886), we report immune responses in 80 patients with blood cancer who received a fourth dose of BNT162b2. We measured neutralizing antibody titers (NAbTs) using a live virus microneutralization assay against wild-type (WT), Delta, and Omicron BA.1 and BA.2 and T cell responses against WT and Omicron BA.1 using an activation-induced marker (AIM) assay. The proportion of patients with detectable NAb titers and T cell responses after the fourth vaccine dose increased compared with that after the third vaccine dose. Patients who received B cell-depleting therapies within the 12 months before vaccination have the greatest risk of not having detectable NAbT. In addition, we report immune responses in 57 patients with breakthrough infections after vaccination.
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; T cells; blood cancer; neutralizing antibodies; variants of concern

Mesh：

Substances：

Year:  2022        PMID： 36240755      PMCID： PMC9513326          DOI： 10.1016/j.xcrm.2022.100781

Source DB:  PubMed          Journal:  Cell Rep Med        ISSN： 2666-3791


  26 in total

1.  Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.

Authors:  Daichi Yamasoba; Izumi Kimura; Hesham Nasser; Yuhei Morioka; Naganori Nao; Jumpei Ito; Keiya Uriu; Masumi Tsuda; Jiri Zahradnik; Kotaro Shirakawa; Rigel Suzuki; Mai Kishimoto; Yusuke Kosugi; Kouji Kobiyama; Teppei Hara; Mako Toyoda; Yuri L Tanaka; Erika P Butlertanaka; Ryo Shimizu; Hayato Ito; Lei Wang; Yoshitaka Oda; Yasuko Orba; Michihito Sasaki; Kayoko Nagata; Kumiko Yoshimatsu; Hiroyuki Asakura; Mami Nagashima; Kenji Sadamasu; Kazuhisa Yoshimura; Jin Kuramochi; Motoaki Seki; Ryoji Fujiki; Atsushi Kaneda; Tadanaga Shimada; Taka-Aki Nakada; Seiichiro Sakao; Takuji Suzuki; Takamasa Ueno; Akifumi Takaori-Kondo; Ken J Ishii; Gideon Schreiber; Hirofumi Sawa; Akatsuki Saito; Takashi Irie; Shinya Tanaka; Keita Matsuno; Takasuke Fukuhara; Terumasa Ikeda; Kei Sato
Journal:  Cell       Date:  2022-05-02       Impact factor: 66.850

2.  Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.

Authors:  Annika Fendler; Scott T C Shepherd; Lewis Au; Katalin A Wilkinson; Mary Wu; Andreas M Schmitt; Zayd Tippu; Sheima Farag; Aljosja Rogiers; Ruth Harvey; Eleanor Carlyle; Kim Edmonds; Lyra Del Rosario; Karla Lingard; Mary Mangwende; Lucy Holt; Hamid Ahmod; Justine Korteweg; Tara Foley; Taja Barber; Andrea Emslie-Henry; Niamh Caulfield-Lynch; Fiona Byrne; Benjamin Shum; Camille L Gerard; Daqi Deng; Svend Kjaer; Ok-Ryul Song; Christophe Queval; Caitlin Kavanagh; Emma C Wall; Edward J Carr; Sina Namjou; Simon Caidan; Mike Gavrielides; James I MacRae; Gavin Kelly; Kema Peat; Denise Kelly; Aida Murra; Kayleigh Kelly; Molly O'Flaherty; Robyn L Shea; Gail Gardner; Darren Murray; Nadia Yousaf; Shaman Jhanji; Nicholas Van As; Kate Young; Andrew J S Furness; Lisa Pickering; Rupert Beale; Charles Swanton; Sonia Gandhi; Steve Gamblin; David L V Bauer; George Kassiotis; Michael Howell; Emma Nicholson; Susanna Walker; Robert J Wilkinson; James Larkin; Samra Turajlic
Journal:  Cancer Cell       Date:  2021-12-29       Impact factor: 31.743

3.  Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.

Authors:  Annika Fendler; Scott T C Shepherd; Lewis Au; Mary Wu; Ruth Harvey; Andreas M Schmitt; Zayd Tippu; Benjamin Shum; Sheima Farag; Aljosja Rogiers; Eleanor Carlyle; Kim Edmonds; Lyra Del Rosario; Karla Lingard; Mary Mangwende; Lucy Holt; Hamid Ahmod; Justine Korteweg; Tara Foley; Taja Barber; Andrea Emslie-Henry; Niamh Caulfield-Lynch; Fiona Byrne; Daqi Deng; Svend Kjaer; Ok-Ryul Song; Christophe Queval; Caitlin Kavanagh; Emma C Wall; Edward J Carr; Simon Caidan; Mike Gavrielides; James I MacRae; Gavin Kelly; Kema Peat; Denise Kelly; Aida Murra; Kayleigh Kelly; Molly O'Flaherty; Robyn L Shea; Gail Gardner; Darren Murray; Nadia Yousaf; Shaman Jhanji; Kate Tatham; David Cunningham; Nicholas Van As; Kate Young; Andrew J S Furness; Lisa Pickering; Rupert Beale; Charles Swanton; Sonia Gandhi; Steve Gamblin; David L V Bauer; George Kassiotis; Michael Howell; Emma Nicholson; Susanna Walker; James Larkin; Samra Turajlic
Journal:  Lancet       Date:  2022-01-25       Impact factor: 79.321

4.  Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study.

Authors:  Adam S Lauring; Mark W Tenforde; James D Chappell; Manjusha Gaglani; Adit A Ginde; Tresa McNeal; Shekhar Ghamande; David J Douin; H Keipp Talbot; Jonathan D Casey; Nicholas M Mohr; Anne Zepeski; Nathan I Shapiro; Kevin W Gibbs; D Clark Files; David N Hager; Arber Shehu; Matthew E Prekker; Heidi L Erickson; Matthew C Exline; Michelle N Gong; Amira Mohamed; Nicholas J Johnson; Vasisht Srinivasan; Jay S Steingrub; Ithan D Peltan; Samuel M Brown; Emily T Martin; Arnold S Monto; Akram Khan; Catherine L Hough; Laurence W Busse; Caitlin C Ten Lohuis; Abhijit Duggal; Jennifer G Wilson; Alexandra June Gordon; Nida Qadir; Steven Y Chang; Christopher Mallow; Carolina Rivas; Hilary M Babcock; Jennie H Kwon; Natasha Halasa; Carlos G Grijalva; Todd W Rice; William B Stubblefield; Adrienne Baughman; Kelsey N Womack; Jillian P Rhoads; Christopher J Lindsell; Kimberly W Hart; Yuwei Zhu; Katherine Adams; Stephanie J Schrag; Samantha M Olson; Miwako Kobayashi; Jennifer R Verani; Manish M Patel; Wesley H Self
Journal:  BMJ       Date:  2022-03-09

5.  Rapid emergence of SARS-CoV-2 Omicron variant is associated with an infection advantage over Delta in vaccinated persons.

Authors:  Chrispin Chaguza; Andreas Coppi; Rebecca Earnest; David Ferguson; Nicholas Kerantzas; Frederick Warner; H Patrick Young; Mallery I Breban; Kendall Billig; Robert Tobias Koch; Kien Pham; Chaney C Kalinich; Isabel M Ott; Joseph R Fauver; Anne M Hahn; Irina R Tikhonova; Christopher Castaldi; Bony De Kumar; Christian M Pettker; Joshua L Warren; Daniel M Weinberger; Marie L Landry; David R Peaper; Wade Schulz; Chantal B F Vogels; Nathan D Grubaugh
Journal:  Med (N Y)       Date:  2022-04-06

6.  SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals.

Authors:  Simone I Richardson; Vimbai Sharon Madzorera; Holly Spencer; Nelia P Manamela; Mieke A van der Mescht; Bronwen E Lambson; Brent Oosthuysen; Frances Ayres; Zanele Makhado; Thandeka Moyo-Gwete; Nonkululeko Mzindle; Thopisang Motlou; Amy Strydom; Adriano Mendes; Houriiyah Tegally; Zelda de Beer; Talita Roma de Villiers; Annie Bodenstein; Gretha van den Berg; Marietjie Venter; Tulio de Oliviera; Veronica Ueckermann; Theresa M Rossouw; Michael T Boswell; Penny L Moore
Journal:  Cell Host Microbe       Date:  2022-03-25       Impact factor: 31.316

7.  Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.

Authors:  Yinon M Bar-On; Yair Goldberg; Micha Mandel; Omri Bodenheimer; Ofra Amir; Laurence Freedman; Sharon Alroy-Preis; Nachman Ash; Amit Huppert; Ron Milo
Journal:  N Engl J Med       Date:  2022-04-05       Impact factor: 91.245

8.  Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron.

Authors:  Maximilian J Mair; Manfred Mitterer; Pia Gattinger; Julia M Berger; Wolfgang Trutschnig; Arne C Bathke; Margaretha Gansterer; Anna S Berghoff; Severin Laengle; Lynn Gottmann; Thomas Buratti; Helmuth Haslacher; Wolfgang W Lamm; Markus Raderer; Selma Tobudic; Thorsten Fuereder; Rudolf Valenta; Dominic Fong; Matthias Preusser
Journal:  Cancer Cell       Date:  2022-04-12       Impact factor: 38.585

Review 9.  Cancer, COVID-19, and Antiviral Immunity: The CAPTURE Study.

Authors:  Lewis Au; Laura Amanda Boos; Anthony Swerdlow; Fiona Byrne; Scott T C Shepherd; Annika Fendler; Samra Turajlic
Journal:  Cell       Date:  2020-09-03       Impact factor: 41.582

10.  Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains.

Authors:  Nikhil Faulkner; Kevin W Ng; Mary Y Wu; Ruth Harvey; Marios Margaritis; Stavroula Paraskevopoulou; Catherine Houlihan; Saira Hussain; Maria Greco; William Bolland; Scott Warchal; Judith Heaney; Hannah Rickman; Moria Spyer; Daniel Frampton; Matthew Byott; Tulio de Oliveira; Alex Sigal; Svend Kjaer; Charles Swanton; Sonia Gandhi; Rupert Beale; Steve J Gamblin; John W McCauley; Rodney Stuart Daniels; Michael Howell; David Bauer; Eleni Nastouli; George Kassiotis
Journal:  Elife       Date:  2021-07-29       Impact factor: 8.140
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.